ACM
APGE

ADAR1 Capital Management’s Apogee Therapeutics APGE Stock Holding History

ADAR1 Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.11M Buy
+31,000
New +$2.79M 0.19% 110
2025
Q3 		– Sell
-18,070
Closed -$785K – 220
2025
Q2 		$785K Sell
18,070
-86,783
-83% -$3.3M 0.12% 97
2025
Q1 		$3.92M Buy
104,853
+63,579
+154% +$2.46M 0.73% 39
2024
Q4 		$1.87M Sell
41,274
-15,909
-28% -$811K 0.37% 50
2024
Q3 		$3.36M Buy
57,183
+16,308
+40% +$781K 0.55% 36
2024
Q2 		$1.61M Buy
40,875
+34,875
+581% +$1.69M 0.3% 50
2024
Q1 		$399K Buy
+6,000
New +$262K 0.09% 92

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

ADAR1 Capital Management's APGE Position: Q2 2026 in Review

ADAR1 Capital Management opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 31,000 shares worth $4.11M. The stake represents 0.19% of the portfolio and ranks #110 among its holdings. This is a return to the name: ADAR1 Capital Management previously reported a position in APGE as recently as Q2 2025.

ADAR1 Capital Management first reported a position in APGE in Q1 2024 and has held it in 7 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • ADAR1 Capital Management held 31,000 shares of Apogee Therapeutics worth $4.11M as of Q2 2026.
  • Apogee Therapeutics was a new ADAR1 Capital Management position in Q2 2026.
  • Apogee Therapeutics made up 0.19% of ADAR1 Capital Management's portfolio in Q2 2026, its #110 holding.
  • ADAR1 Capital Management first reported a position in Apogee Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.